Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Respiratory, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TBXA2R drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | TBXA2R Promise-ORF / Lentivirus Premade Particles (VSV-G Pseudotyped, >10^8 TU/mL). Full-length ORF for stable cell lines. Essential for GPCR conformation. Options with C-terminal tGFP/mCherry. | View TBXA2R Products |
| ORF Clone | TBXA2R Promise-ORF Vector; Sequence Verified, ready for stable cell line construction. Also available for Human/Mouse/Cyno. | View TBXA2R Products |
| Benchmark Ab | Anti-TBXA2R (Research Grade); Recombinant monoclonal for flow cytometry, receptor occupancy, and positive control. Sequence Verified. | View TBXA2R Products |
| Validator | TBXA2R siRNA Set (3 unique sequences); For knockdown verification and assay specificity control. | View TBXA2R Products |
| Related Target A | PTGIS (Prostacyclin synthase); functional counter-balance in vascular homeostasis. | View PTGIS Products |
| Related Target B | PTGS1 (COX-1); upstream enzyme in thromboxane production. | View PTGS1 Products |
| Related Target C | PTGFR (Prostaglandin F2-alpha Receptor); synergistic prostanoid pathway; counter-screening for selectivity panels. | View PTGFR Products |
| Related Target D | PTGER1 (Prostaglandin E Receptor 1, EP1); Gq-coupled; calcium mobilization cross-talk analysis. | View PTGER1 Products |
| Related Target E | TBXAS1 (Thromboxane A Synthase 1); upstream enzyme; complementary target for dual-pathway inhibition. | View TBXAS1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation / Native Preservation | Lentivirus premade particles for stable cell line generation. Ensures native folding, glycosylation, and ligand binding fidelity for Calcium Flux and internalization assays. |
| Prostanoid Receptor Selectivity (EP1, EP3, FP, DP, IP) | Homolog panel cell lines (PTGFR, PTGER1, PTGER3) strictly verified by sequence analysis or mass spec. |
| Cross-species Evaluation (mouse, cyno) | Human/Mouse/Cyno TBXA2R ORF clones available; >95% alignment coverage. |
| Lack of Controls / False Positives in Calcium Flux | Recombinant positive control antibodies included; validated siRNA for specificity checks; GFP-control lentivirus for baseline correction. |
| Binding Site Verification (Allosteric vs Orthosteric) | Full-length vs mutant receptor panels available for binding site mapping. |
Live TBXA2R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Antagonist Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The TBXA2R therapeutic landscape is experiencing a strategic shift from traditional cardiovascular antiplatelet indications toward respiratory and oncology applications. While first-generation small-molecule antagonists (ifetroban, seratrodast) established proof-of-mechanism in thrombosis and asthma, current R&D focuses on highly selective modulators with improved PK profiles for chronic respiratory diseases and novel inhibitors targeting the tumor-platelet axis in metastasis. The next wave of discovery emphasizes allosteric modulators and tissue-specific formulations (inhaled vs. systemic) to minimize bleeding risks while maximizing efficacy in pulmonary hypertension and allergic inflammation. Additionally, emerging research indicates roles in cancer metastasis and tumor microenvironment modulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Bayer, Sanofi, Toho University | Cardiovascular, Asthma, Thrombosis | Calcium Flux Assay (Need stable cell lines with high receptor density) |
| Monoclonal Ab | Emerging Biotechs | Oncology (Metastasis) | Receptor Binding Assay (Need native conformation) |
| Allosteric Modulator | Academic Consortia | Pulmonary Hypertension | Binding Site Verification (Need full-length vs mutant receptor panels) |
| Dual Antagonist (TBXA2R/TP) | Various / Oncology Biotechs | Thrombosis, Metastatic Cancer | Selectivity Assay (Need homolog panel cell lines) |
| Inhaled Formulation | Respiratory Specialists | Severe Asthma | Receptor Occupancy (Need high-affinity benchmark antibodies) |
Target Genetics and Variants
The thromboxane A2 receptor gene (TBXA2R) harbors several clinically relevant variants. The R60L mutation (BDPLT13) does not affect TXA2 binding but leads to defective interaction with G proteins, implicating it in platelet dysfunction. Two common single-nucleotide polymorphisms, rs5743 and rs5744 (dbSNP), have been associated with altered receptor function and disease susceptibility. Understanding these variants is critical for patient stratification and for evaluating compound efficacy across genetic backgrounds. TarMart provides wild-type and mutant TBXA2R ORF clones for such studies.